<DOC>
	<DOCNO>NCT02220296</DOCNO>
	<brief_summary>This trial conduct Europe . The purpose evaluate safety tolerability range single dose subcutaneous insulin 338 .</brief_summary>
	<brief_title>A Trial Investigating Safety , Tolerability , Pharmacokinetics Pharmacodynamics Subcutaneous NNC0123-0338 Healthy Subjects Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Trial Part 1 ( Healthy subject ) : Male subject Age 1855 ( inclusive ) time sign inform consent Body mass index 19.029.9 kg/m^2 ( inclusive ) Trial Part 2 ( Subjects type 1 diabetes mellitus ) : Male subject female subject nonchild bearing potential . Nonchild bear potential : surgically sterilize ( i.e . tubal ligation , bilateral oopherectomies hysterectomised ) 3 month postmenopausal ( define amenorrhoea least 2 year prior screen document folliclestimulating hormone ( FSH ) 40 U/L ) Age 1864 year ( inclusive ) time sign inform consent Body mass index 19.029.9 kg/m^2 ( inclusive ) Type 1 diabetes mellitus ( diagnose clinically ) 12 month longer Treated multiple daily insulin injection insulin pump treatment 12 month longer Glycated hemoglobin ( HbA1c ) 9.0 % less Fasting Cpeptide less 0.3 nmol/L Trial Part 1 ( healthy subject ) : History , presence , cancer , diabetes mellitus clinically significant cardiovascular , respiratory , metabolic ( include dyslipidemia ) , renal , hepatic , gastrointestinal , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder , judge investigator Increased risk thrombosis , e.g . subject history deep leg vein thrombosis family history deep leg vein thrombosis , judge investigator Currently smoke 1 cigarette per day ( equivalent tobacco product ) smoke 1 cigarette less per day consider able refrain smoking refrain use type nicotine product ( e.g . chew tobacco , nicotine gum ) inhouse period Trial Part 2 ( subject type 1 diabetes mellitus ) : History , presence , cancer clinically significant respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological ( exception condition associate diabetes mellitus ) , haematological , dermatological , venereal , neurological , psychiatric , major disorder personal and/or family history thromboembolism , judge investigator Increased risk thrombosis , e.g . subject history deep leg vein thrombosis family history deep leg vein thrombosis , judge investigator Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge Investigator hospitalisation diabetic ketoacidosis past 6 month start trial ( screen ) Cardiac problem define : 1 ) decompensated heart failure ( New York Heart Association ( NYHA ) class III IV ) time , 2 ) acute myocardial infarction time , 3 ) angina pectoris within last 12 month start trial ( screen ) Currently smoke 1 cigarette per day ( equivalent tobacco product ) smoke 1 cigarette less per day consider able refrain smoking refrain use type nicotine product ( e.g . chew tobacco , nicotine gum ) inhouse period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>